What is AgeneBio?
AgeneBio operates at the intersection of biotechnology and neurology, focusing on the development of innovative therapeutics designed to preserve cognitive function. The company is currently prioritizing a late-stage clinical program aimed at mitigating the progression of Alzheimer's dementia. Beyond its primary focus, AgeneBio maintains a diversified research portfolio targeting mild cognitive impairment, autism, and schizophrenia. By addressing these critical psychiatric and neurological conditions, the firm positions itself as a pivotal player in the global effort to improve patient outcomes and reduce the societal burden of neurodegenerative diseases.
How much funding has AgeneBio raised?
AgeneBio has raised a total of $17.8M across 6 funding rounds:
Debt
$3.7M
Other Financing Round
$1M
Other Financing Round
$1M
Private Equity
$4.1M
Grant
$7.5M
Grant
$500K
Debt (2010): $3.7M, investors not publicly disclosed
Other Financing Round (2013): $1M, investors not publicly disclosed
Other Financing Round (2013): $1M, investors not publicly disclosed
Private Equity (2014): $4.1M, investors not publicly disclosed
Grant (2015): $7.5M backed by National Institutes of Health
Grant (2019): $500K with participation from The Alzheimer's Drug Discovery Foundation
Key Investors in AgeneBio
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical grant support for high-impact medical innovation.
The Alzheimer's Drug Discovery Foundation
A specialized philanthropic organization dedicated to accelerating the discovery and development of innovative drugs to prevent, treat, and cure Alzheimer's disease.
Undisclosed Investor
An undisclosed investor participating in the funding round, providing essential capital to support the company's ongoing clinical research and development initiatives.
What's next for AgeneBio?
With the recent influx of capital, AgeneBio is well-positioned to accelerate its clinical development milestones. The strategic allocation of these funds will likely focus on advancing its lead therapeutic candidates through the final stages of clinical trials and regulatory review. As the company transitions toward potential commercialization, the focus will shift from early-stage discovery to large-scale clinical validation and market entry preparation. Investors and stakeholders will be closely monitoring the firm's ability to translate its scientific breakthroughs into viable, FDA-approved treatments that address significant unmet medical needs in the aging population.
See full AgeneBio company page
